The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- South London Stroke Research NetworkFulltext
Final published version, 1.03 MB, PDF document
Introduction: There are few randomized clinical trials in vascular cognitive impairment (VCI). This trial tested the hypothesis that the PDE5 inhibitor tadalafil, a widely used vasodilator, increases cerebral blood flow (CBF) in older people with symptomatic small vessel disease, the main cause of VCI. Methods: In a double-blind, placebo-controlled, cross-over trial, participants received tadalafil (20 mg) and placebo on two visits ≥7 days apart (randomized to order of treatment). The primary endpoint, change in subcortical CBF, was measured by arterial spin labelling. Results: Tadalafil increased CBF non-significantly in all subcortical areas (N = 55, age: 66.8 (8.6) years) with greatest treatment effect within white matter hyperintensities (+9.8%, P =.0960). There were incidental treatment effects on systolic and diastolic blood pressure (–7.8, –4.9 mmHg; P <.001). No serious adverse events were observed. Discussion: This trial did not identify a significant treatment effect of single-administration tadalafil on subcortical CBF. To detect treatment effects may require different dosing regimens.
Original language | English |
---|---|
Journal | Alzheimer's & Dementia |
Volume | 18 |
Issue number | 12 |
Pages (from-to) | 2393-2402 |
Number of pages | 10 |
ISSN | 1552-5260 |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
Publisher Copyright:
Alzheimer's & Dementia© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
- cerebral blood flow, clinical trials, PDE5, small vessel disease, tadalafil, vascular cognitive impairment, vascular cognitive impairment and dementia
Research areas
ID: 313702946